Digital health startup based in Türkiye water therapy The company announced that Foggy, a new walk-instruction freeze feature for Apple Watch designed for people with Parkinson's disease, is now listed by the FDA as a Class II medical device and available by prescription.
by Parkinson's Disease Foundation, Freezing of the gait is a symptom of Parkinson's disease in which patients are temporarily unable to move involuntarily. Freezing can also affect a person's speech and other parts of their body.
h2otherapys is an augmented reality, AI, and mobile-based digital therapeutics company. The company also offers a smartwatch system for early detection of coronavirus disease (COVID-19) called Covie.
Foggy leverages the Apple Watch's Taptic Engine to provide vibrotactile stimulation when patients are experiencing a freezing gait. When a user taps on a complication, feedback is initiated to help with the condition.
The feature is available through the company's Parky app, which Apple Watch users can access with a prescription.
”Signaling strategies hold great promise in helping people with freezing gait. However, the key to its effectiveness lies in accessibility, personalization, and ease of use. „Our introduction of Foggy is a major advance in this field, offering patients a non-invasive solution by simply wearing their Apple Watch, designed to assist without adding cognitive load.“ , Yagramul Serin Gulums, founder of H2O therapy, said in a statement.
bigger trends
Perky received FDA approval This application monitors Parkinson's symptoms such as tremors and movement disorders.
water therapy Partnered with AmerisourceBergen The company will bring its Parky app to market in 2023.
AmerisourceBergen supported the integration of h2o into the healthcare system and helped create patient engagement through AmerisourceBergen's digital care platform. The DTx platform allows physicians to order and fulfill digital treatments.
Other companies in the wearable surveillance market include the following Washington-based companies: NeuroRPM and activation of brain data rune lab.
rune lab locked down A Parkinson's disease symptom monitoring app called StrivePD will receive FDA approval in 2022. The application also uses the Apple Watch's monitoring capabilities to track uncontrolled body movements.
rune lab partnered In 2023, we will partner with biopharmaceutical research company BlueRock Therapeutics to further research Parkinson's disease using the Rune Labs StriveStudy clinical platform and the company's monitoring app StrivePD.
NeuroRPM Obtained FDA approval In 2023, a Parkinson's disease monitoring app will be developed that leverages AI to monitor common Parkinson's symptoms such as tremor and bradykinesia.